G9a and GLP are frequently overexpressed in several cancers, and enzymatic inhibitors of GLP/G9a have been developed and proved effective in the inhibition of the growth of certain cancer types in vitro and in vivo31,32, representing a promising therapeutic agent in cancer treatment. Here, EHMT2 is linked to cancer.